Trial
NCT05509582
Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborators
—
Condition
Immune Mediated Anemia
Intervention
fostamatinib
Why stopped
No responders in parent protocol 000758; this follow-on protocol not activated and PI leaving NIH
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-11-10